Cargando…

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma

BACKGROUND: Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on the clinical features and prognostic factors. PATIENTS AND METHODS: A consecutive cohort of patients with PB-DLBCL was retrospectively analyzed in our hospital fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Guang-Liang, Li, Doudou, Cao, Sufen, Jiang, Shiyu, Zhang, Qunling, Jin, Jia, Xia, Zuguang, Liu, Yizhen, Liu, Xiaojian, Zhu, Yanzhe, Chen, Yu, Gu, Lingli, Hong, Xiaonan, Cao, Junning, Tao, Rong, Lv, Fangfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448260/ https://www.ncbi.nlm.nih.gov/pubmed/36119461 http://dx.doi.org/10.4084/MJHID.2022.066

Ejemplares similares

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma
por: Liu, Yizhen, et al.
Publicado: (2020)

Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma
por: Liu, Yizhen, et al.
Publicado: (2022)

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T‐cell lymphoma patients
por: Liu, Yizhen, et al.
Publicado: (2020)

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
por: Zhang, Yao, et al.
Publicado: (2021)

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial
por: Jin, Jia, et al.
Publicado: (2022)

Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma
por: Qiu, Shi, et al.
Publicado: (2022)

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study
por: Ji, Dongmei, et al.
Publicado: (2016)

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial
por: Xue, Kai, et al.
Publicado: (2016)

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR
por: Jin, Jia, et al.
Publicado: (2020)

Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma
por: Chen, Guang-Liang, et al.
Publicado: (2021)

Prognostic Significance of LDH Ratio in Serum/Cerebral Spinal Fluid of Patients with Primary Testicular Diffuse Large B-Cell Lymphoma
por: Liu, Yi-Zhen, et al.
Publicado: (2019)

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma
por: Singh, Anil R., et al.
Publicado: (2020)

Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis
por: Li, Shengjie, et al.
Publicado: (2022)

Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma
por: Cao, Di, et al.
Publicado: (2021)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Prognostic Significance of Ribosome-related Genes Signature in Diffuse Large B Cell Lymphoma
por: Wu, Wenqi, et al.
Publicado: (2023)

Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study
por: HUANG, HONG-HUI, et al.
Publicado: (2012)

PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma
por: Chen, Jianfeng, et al.
Publicado: (2020)

Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor
por: Ji, Dongmei, et al.
Publicado: (2023)

The Addition of Ferritin Enhanced the Prognostic Value of International Prognostic Index in Diffuse Large B‐Cell Lymphoma
por: Shen, Ziyuan, et al.
Publicado: (2022)

Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
por: Liu, Ran, et al.
Publicado: (2019)

Centrality-based pathway enrichment: a systematic approach for finding significant pathways dominated by key genes
por: Gu, Zuguang, et al.
Publicado: (2012)

Prognostic and clinicopathological role of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: A meta-analysis
por: Cao, Dan, et al.
Publicado: (2023)

Methylation silencing CDH23 is a poor prognostic marker in diffuse large B-cell lymphoma
por: Cao, Baoping, et al.
Publicado: (2021)

Metadherin Contributes to the Pathogenesis of Diffuse Large B-cell Lymphoma
por: Ge, Xueling, et al.
Publicado: (2012)

An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma
por: Zhou, Fenling, et al.
Publicado: (2023)

Prognostic value of nutritional status in patients with human immunodeficiency virus infection-related lymphoma
por: Liu, TingTing, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes
por: Sun, Yao, et al.
Publicado: (2016)

Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study
por: Cao, Jiazhen, et al.
Publicado: (2023)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

C-MYC Aberrations as Prognostic Factors in Diffuse Large B-cell Lymphoma: A Meta-Analysis of Epidemiological Studies
por: Zhou, Kuangguo, et al.
Publicado: (2014)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Prognostic impact of C-REL expression in diffuse large B-cell lymphoma
por: Curry, Choladda V, et al.
Publicado: (2009)

Identification of a prognostic metabolic gene signature in diffuse large B‐cell lymphoma
por: Wang, Huizhong, et al.
Publicado: (2021)

Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP
por: Wang, Jing, et al.
Publicado: (2016)

Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma
por: Zhou, Xiaonan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k6j1bposrsa4idnv6685q7lbqj